WASHINGTON — Biogen is calling Medicare’s bluff.
The federal health insurance program for people 65 and older proposed to drastically limit how often it would pay for the embattled biotech’s controversial Alzheimer’s drug, Aduhelm, a blow to Biogen’s hopes for wide uptake among Medicare patients. Medicare said it needed more information about the drug’s efficacy and safety and said it would only pay for the drug for patients enrolled in clinical trials.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
